STOCK TITAN

Benitec Biopharm - BNTC STOCK NEWS

Welcome to our dedicated page for Benitec Biopharm news (Ticker: BNTC), a resource for investors and traders seeking the latest updates and insights on Benitec Biopharm stock.

Benitec Biopharma Inc. (BNTC) is a clinical-stage biotechnology leader advancing novel genetic medicines through its patented DNA-directed RNA interference (ddRNAi) technology. This page provides investors and industry professionals with essential updates on the company’s therapeutic developments, strategic partnerships, and scientific milestones.

Access authoritative information on Benitec’s Silence and Replace platform progress, including clinical trial results for conditions like Oculopharyngeal Muscular Dystrophy. Stay informed about regulatory filings, intellectual property expansions, and collaborative research initiatives through verified press releases and official announcements.

Key updates include progress reports on lead candidate BB-301, licensing agreements supporting platform commercialization, and peer-reviewed data validating the company’s gene-silencing approach. All content is sourced directly from company communications to ensure accuracy and compliance with financial disclosure standards.

Bookmark this page for streamlined access to Benitec’sopharma’s latest developments in genetic medicine. Check regularly for real-time updates on pipeline advancements and strategic decisions shaping the future of one-shot genetic therapies.

Rhea-AI Summary
Benitec Biopharma Inc. announces a virtual R&D Day to discuss gene therapy for oculopharyngeal muscular dystrophy. Key opinion leaders will review clinical symptoms, disease progression, and treatment landscape.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
conferences
-
Rhea-AI Summary
Benitec Biopharma Inc. announces the dosing of the first subject with BB-301 in a Phase 1b/2a clinical treatment study for Oculopharyngeal Muscular Dystrophy. No dose-limiting toxicities observed, with positive recommendations for subject enrollment continuation. Financially, the company reported total revenues of $0, total expenses of $6.9 million, and a net loss of $6.8 million for the quarter ended December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
-
Rhea-AI Summary
Benitec Biopharma Inc. (NASDAQ: BNTC) has initiated the first clinical trial using its 'Silence and Replace' DNA-directed RNA interference gene therapy platform. The trial, called BB-301, is for the treatment of Oculopharyngeal Muscular Dystrophy-related Dysphagia, a chronic, life-threatening genetic disorder affecting approximately 15,000 patients in the United States, Canada, Western Europe, and Israel. The first subject has been dosed, marking the beginning of a 52-week follow-up period to evaluate primary and secondary endpoints. Interim safety and efficacy evaluations will be conducted every 90 days. The company aims to improve the lives of patients suffering from OPMD through its gene therapy approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
Rhea-AI Summary
Benitec Biopharma Inc. (NASDAQ: BNTC) announced that Jerel A. Banks, M.D., Ph.D., will participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference. The live webcast will be accessible from the Investor section of Benitec’s website at ir.benitec.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.46%
Tags
conferences
-
Rhea-AI Summary
Benitec Biopharma Inc. (NASDAQ: BNTC) announced financial results for Q1 2024, including the enrollment of 19 subjects in the OPMD Natural History Study and the upcoming BB-301 Phase 1b/2a Clinical Treatment Study. The company also provided operational and regulatory updates, as well as financial highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
-
Rhea-AI Summary
Benitec Biopharma receives FDA clearance for BB-301 IND application for the treatment of OPMD-related dysphagia. Successful closing of a $30.9M public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
Rhea-AI Summary
Benitec Biopharma Inc. has closed its underwritten public offering, raising approximately $30.9 million. The company sold 15,544,041 shares of common stock and accompanying warrants at a combined offering price of $1.93. The proceeds will be used to support the clinical development of BB-301 and other product candidates, as well as for general corporate purposes and strategic growth opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
-
Rhea-AI Summary
Benitec Biopharma Inc. announces pricing of public offering, expected to raise approximately $30 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
65.8%
Tags
-
Rhea-AI Summary
Benitec Biopharma Inc. (NASDAQ: BNTC) will effect a 1-for-17 reverse stock split of its common stock to maintain its listing on Nasdaq. The split will become effective on July 26, 2023, and the stock will begin trading on a split-adjusted basis. The reverse split will combine 17 current shares into one share. No fractional shares will be issued.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
none
Rhea-AI Summary
Benitec Biopharma has received FDA clearance for its Investigational New Drug (IND) application for BB-301, a gene therapy for the treatment of Oculopharyngeal Muscular Dystrophy-related Dysphagia. The first subject is expected to be dosed in the second half of 2023, following the rollover of subjects from the ongoing Natural History (NH) study. OPMD is a chronic, life-threatening genetic disorder affecting approximately 15,000 patients in the United States, Canada, Western Europe, and Israel. Currently, there are no approved therapeutic agents for the treatment of OPMD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
80.9%
Tags
Benitec Biopharm

Nasdaq:BNTC

BNTC Rankings

BNTC Stock Data

351.26M
24.73M
3.49%
85.61%
0.75%
Biotechnology
Pharmaceutical Preparations
Link
United States
HAYWARD